RVMD - Spark Newswire

2 minute read

Earnings

Revolution Medicines’s Return On Capital Employed Overview

Today, 2:52 PM

Revolution Medicines (NASDAQ:RVMD) brought in sales totaling $7.58 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 9.44%, resulting in a loss of $57.65 million.

RVMD

1 minute read

B of A Securities Initiates Coverage On Revolution Medicines with Neutral Rating, Announces Price Target of $24

By Benzinga Newsdesk

Today, 2:52 PM

B of A Securities analyst Alec Stranahan initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Neutral rating and announces Price Target of $24.

RVMD

16 minute read

Earnings Scheduled For May 9, 2022

By Benzinga Insights

Today, 2:52 PM

Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.

ACM

2 minute read

Children’s Place And 2 Other Stocks Bought By Insiders

By Lisa Levin

Today, 2:52 PM

Although the Dow Jones traded higher this morning on Friday, there were a few notable insider trades.

ITOS

2 minute read

Insiders Buy More Than $3B Of 4 Stocks

By Lisa Levin

Today, 2:52 PM

Although US stock futures traded lower this morning amid rising Russia-Ukraine concerns, there were a few notable insider trades.

DKNG

22 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 2:52 PM

On Friday, 368 stocks hit new 52-week lows.

AAL

13 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For March 1, 2022

By Benzinga Insights

Today, 2:52 PM

Upgrades

ACLX

1 minute read

Stifel Upgrades Revolution Medicines to Buy, Lowers Price Target to $26

By Benzinga Newsdesk

Today, 2:52 PM

Stifel analyst Benjamin Burnett upgrades Revolution Medicines (NASDAQ:RVMD) from Hold to Buy and lowers the price target from $36 to $26.

RVMD

10 minute read

Earnings Scheduled For February 28, 2022

By Benzinga Insights

Today, 2:52 PM

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.

AAON

4 minute read

Revolution Medicines Reports Progress Across Pipeline Of Targeted Therapeutics For RAS-Addicted Cancers

By Benzinga Newsdesk

Today, 2:52 PM

Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today reported progress across its pipeline of targeted therapeutics spanning its

RVMD

Feed Symbols: RVMD